Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China, today announced the appointment of Ian Woo to the position of President and Chief Financial Officer. He has also been named Managing Director at the healthcare private equity firm C-Bridge Capital, one of the leading investors in Everest Medicines.
Mr. Woo, an accomplished financial and business executive with more than 18 years of biopharmaceutical and M&A experience, will help expand Everest’s efforts to license, develop and commercialize a broad portfolio of products in China and other Asian markets.
“Ian has a proven track record of managing cross-border transactions,” said Fu Wei, CEO of C-Bridge Capital. “As part of our team, he will help lead the acceleration of Everest’s licensing and development efforts for biopharmaceutical assets from the U.S. and Europe for commercialization in China and neighboring Asian markets.”
Before joining Everest Medicines, Mr. Woo was a managing director in the global healthcare group at Lazard, one of the world's premier financial advisory and asset management firms. He covered global biopharma companies and led Lazard’s healthcare efforts in Greater China. Mr. Woo joined Lazard in 2005 and was based in New York, other than from 2012 to 2016, when he worked in the firm’s Hong Kong office. Throughout his investment banking career, Mr. Woo helped raise over $1.0 billion in equity financings and advised on more than $35 billion in M&A transactions.
“We are delighted to welcome Ian to the team,” said Sean Cao, Ph.D., interim CEO of Everest Medicines. “Ian joins Everest after its successful launch. We are thrilled to have his unparalleled insights into the biopharma industry and corporate finance as we continue to grow.”
“I decided to join Everest Medicines and C-Bridge because of the exceptional team they have built, the late-stage pipeline Everest has assembled, and the ability to deploy the capital needed to succeed,” said Mr. Woo. “I am truly excited about the unique opportunity to build Everest into the partner of choice for companies looking to gain access to the fast-growing China markets.”
Ian holds a Masters of Business Administration from Columbia University Business School, a Master’s degree in Molecular and Cellular Biology from Columbia University Graduate School of Arts & Sciences and a Bachelor’s degree in Biology from Tufts University. Mr. Woo was also a student at Harvard University Graduate School of Arts & Sciences, and conducted research at Harvard Medical School and Brigham and Women’s Hospital, where he was an author on multiple published papers.
Everest Medicines is a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China. The Everest Medicines team has deep expertise and an extensive track record of high quality clinical development, regulatory affairs, CMC, business development and operations both in China and for leading global pharmaceutical companies. For more information, please visit its website at www.everestmedicines.com.
C-Bridge Capital is a healthcare dedicated private equity firm, focused on growth and late stage investment opportunities. C-Bridge Capital’s current portfolio includes China’s leading players in pharmaceuticals, medical devices, diagnostics and healthcare services. C-Bridge Capital is committed to supporting commercialization of cutting edge technologies and companies that fulfill unmet medical needs, and continuously improving the standard and quality of care for patients.
James Cen Bonsor
Investor Relations Director
+86 21 8012 7764
Media in US and Europe:
Senior Vice President
Media in China:
Senior Vice President
+86 (10) 6583-7510
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/c4478313-4d6b-48c0-a717-7424f5f9224d
View the press release at Globe Newswire here.